Paniltri (Hydrochlorothiazide, Ramipril, Amlodipine Besilate)

Hydrochlorothiazide, Ramipril and Amlodipine Besilate, the active ingredients in Paniltri, are a combination antihypertensive presented as oral tablets for systemic use. The fixed‑dose combination lowers elevated blood pressure in adult patients by targeting fluid balance, the renin‑angiotensin system and vascular smooth‑muscle tone.

GNH USA supplies Paniltri as a licensed, GDP‑compliant international pharmaceutical supplier, providing quality‑assured products to hospitals, pharmacies and clinics worldwide, with adherence to EU manufacturing standards and robust distribution networks. Our supply chain includes temperature‑controlled logistics where required and comprehensive regulatory documentation for seamless import.

Paniltri, a fixed‑dose combination antihypertensive, is indicated for the management of elevated blood pressure.

- Hypertension: provides effective blood pressure reduction in adults with primary hypertension. - Resistant hypertension: offers an additional therapeutic option when blood pressure remains uncontrolled on two agents. - Hypertension with fluid retention: helps control blood pressure and reduces peripheral edema by combining a diuretic with vasodilators. - Hypertension in chronic kidney disease: slows renal function decline by inhibiting the renin‑angiotensin system.

Paniltri may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate pain in the head region. - Peripheral edema: swelling of ankles or feet. - Cough: dry, persistent throat irritation. - Fatigue: feeling unusually tired or weak. - Increased urination: more frequent need to void.

Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips or throat requiring emergency care. - Severe hypotension: marked drop in blood pressure causing faintness. - Electrolyte imbalance: especially hyperkalemia or hyponatremia. - Acute renal impairment: sudden decline in kidney function. - Hepatic dysfunction: abnormal liver enzyme elevations. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain.

Before initiating therapy, clinicians should consider several safety aspects. - Blood pressure monitoring: ensure target levels are achieved without excessive drop. - Renal function assessment: evaluate serum creatinine and eGFR periodically. - Electrolyte surveillance: check potassium and sodium levels, especially with diuretic use. - Pregnancy and lactation: avoid use unless clearly indicated, as risks may outweigh benefits. - Elderly patients: start at lower doses and monitor for orthostatic symptoms. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Paniltri can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Aliskiren: combined renin inhibition may cause renal dysfunction. - NSAIDs: can blunt antihypertensive effect and increase renal risk. - Potassium‑sparing agents or supplements: heightened risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., clarithromycin): may increase amlodipine concentrations. - Other antihypertensives (e.g., beta‑blockers): additive hypotensive effect. - Non‑potassium‑sparing diuretics: may exacerbate electrolyte disturbances.